Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studiesYing Yuan, Kefeng Ding, Yongdong Jin et al.|Signal Transduction and Targeted Therapy|2025Cited by 14